Biopharma companies are integrating synthetic biology to design novel modalities, optimize production and reach previously intractable targets. Companies like Mammoth Biosciences and others are mining natural diversity, engineering compact CRISPR systems, and applying automation to enable delivery to hard‑to‑reach tissues. At the same time, AI and robotics are accelerating strain engineering, pathway design and biomanufacturing scale‑up. Industry sources highlighted in recent coverage show a shift from academic curiosity to commercial deployment across therapeutics, agricultural biologicals and industrial biotech, with corporate partnerships and R&D investments following the technical advances.